KPV

Common questions about KPV

What is KPV?

KPV is a three-residue fragment (Lysine-Proline-Valine) derived from the C-terminus of α-MSH. It is studied for anti-inflammatory effects in gut and skin preclinical models, and is commonly paired with BPC-157 in gastrointestinal research protocols.

Is KPV FDA-approved?

No. KPV is not approved by the FDA or any major regulator for human use. Research-peptide vendors sell it for laboratory research only.

What is the half-life of KPV?

Published rodent studies report a plasma half-life of roughly 1–2 hours, with PepT1-transporter-mediated tissue accumulation appearing to prolong functional effects beyond the circulating kinetics.

What dose of KPV is used in research?

Doses reported in published preclinical studies vary by species, route, and inflammatory model. Pepticker does not publish a dosing protocol — refer to the original literature for the model you are reproducing.

What is KPV commonly stacked with?

Researchers most commonly pair KPV with BPC-157 in gastrointestinal protocols and with LL-37 in mucosal-immunity work, based on published preclinical research and vendor protocols.

Is KPV legal?

KPV is sold for research use in the US, Canada, and the UK. In Australia it is TGA Schedule 4 and personal import is tightly controlled. Status is informational — not legal advice.

Editorial summary of published research. Not medical advice. See /methodology for sourcing.